Gary Patou

Gary Patou currently works at Xenon Pharmaceuticals, Inc., as Independent Director from 2004, Scleroderma Research Foundation, as Advisor from 2021, and Star Therapeutics, Inc., as Chief Medical Officer from 2020.
Dr. Patou also formerly worked at Cerimon Pharmaceuticals, Inc., as President & Chief Executive Officer from 2008 to 2009, Ligand UK Ltd., as Director in 1995, GSK Plc, as Senior VP, Director-Project & Portfolio Management from 1995 to 2000, Smithkline Beecham Pharmaceuticals Ltd., as Senior VP, Director-Project & Portfolio Management from 1995 to 2000, Biointervene, Inc., as Director & Chief Medical Officer, Oscient Pharmaceuticals Corp., as Chief Medical Officer & Executive Vice President from 2004 to 2005, Genesoft Pharmaceuticals, Inc., as President in 2004, Peplin Ltd., as Chief Medical Officer in 2007, Cerimon Pharmaceuticals, Inc., as Chief Medical Officer from 2005 to 2006, Chiasma, Inc., as Senior Medical Advisor, MPM BioImpact LLC, as Advisor from 2020 to 2022, Pacira Biosciences, Inc., as Chief Medical Officer from 2009 to 2015, True North Therapeutics, Inc., as Chief Medical Officer from 2016 to 2017, and Blade Therapeutics, Inc., as Chief Medical Officer from 2018 to 2020.
Dr. Patou received his undergraduate degree, graduate degree, and doctorate degree from the University of London.